Paid Clinical Trials Cheyenne
Discover 39 paid clinical trials in Cheyenne, Wyoming. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04164082
Conditions
Bladder Flat Urothelial Carcinoma In Situ
Non-Muscle Invasive Bladder Urothelial Carcinoma
Stage 0a Bladder Cancer AJCC v8
Stage 0is Bladder Cancer AJCC v8
Stage I Bladder Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Cystoscopy
Gemcitabine Hydrochloride
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerOsimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04181060
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bevacizumab
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
MILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims StudyMILD® Percutaneous Image-Guided Lumbar Decompression: a Medicare Claims Study
Sponsor:
Vertos Medical, Inc.
Location:
Code:
NCT03072927
Conditions
Lumbar Spinal Stenosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MILD
Interspinous Process Decompression
Reaching Rural Cancer Survivors Who Smoke Using Text-Based ProgramReaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT05008848
Conditions
Cigarette Smoking-Related Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Smoking Cessation Intervention
Health Promotion and Education
Informational Intervention
Questionnaire Administration
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT02201992
Conditions
ALK Gene Rearrangement
ALK Gene Translocation
ALK Positive
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Clinical Observation
Crizotinib
Laboratory Biomarker Analysis
Evaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth ProgramEvaluation of Body Composition Improvement With Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Sponsor:
20Lighter
Location:
Code:
NCT05219240
Conditions
Obesity
Cardiovascular Diseases
Metabolic Syndrome
Metabolic Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
20Lighter Program
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaLenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT03937635
Conditions
Smoldering Plasma Cell Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Daratumumab
Dexamethasone
Lenalidomide
Quality-of-Life Assessment
Questionnaire Administration
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Sponsor:
Amneal Pharmaceuticals, LLC
Location:
Code:
NCT05401357
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Test - Bimatoprost 0.01% Ophthalmic Solution
Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
Intravesical BCG vs GEMDOCE in NMIBCIntravesical BCG vs GEMDOCE in NMIBC
Sponsor:
ECOG-ACRIN Cancer Research Group
Location:
Code:
NCT05538663
Conditions
Non-muscle-invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Gemcitabine
Docetaxel
Bacillus Calmette Guerin
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesTesting Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04647916
Conditions
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Metastatic HER2 Negative Breast Carcinoma
Metastatic Malignant Neoplasm in the Brain
Prognostic Stage IV Breast Cancer AJCC v8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan